U.S. Securities and Exchange Commission
                             Washington, D.C. 20549

                                   Form 10-QSB

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

           For the quarter ended:   September 30, 2001

Commission file no. 0-24921

                         Surgical Safety Products, Inc.
                  --------------------------------------------
                 (Name of small business issuer in its charter)


     New York                                               65-0565144
-------------------------------                        ------------------------
(State or other jurisdiction of                        (I.R.S. Employer
incorporation or organization)                              Identification No.)

One Sarasota Tower, Suite 608
2 North Tamiami Trail, Sarasota, Florida                       34236
---------------------------------------                ------------------------
(Address of principal executive offices)                     (Zip Code)

Issuer's telephone number (941)953-9848

Securities registered under Section 12(b) of the Exchange Act:

      Title of each class                              Name of each exchange on
                                                           which registered
          None
-----------------------------                          -------------------------

Securities registered under Section 12(g) of the Exchange Act:

                          Common Stock, $.001 par value
                       -----------------------------------
                                (Title of class)

Copies of Communications Sent to:

                          Mercedes Travis, Esq.
                          Mintmire & Associates
                          265 Sunrise Avenue, Suite 204, Palm Beach, FL 33480
                          Tel: (561) 832-5696; Fax: (561) 659-5371



<PAGE>



     Indicate by Check  whether the issuer (1) filed all reports  required to be
filed by Section 13 or 15(d) of the  Exchange  Act during the past 12 months (or
for such shorter  period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.

                   Yes  X        No
                       ---         ---

     As of September 30, 2001,  there are  20,022,889  shares of voting stock of
the registrant issued and outstanding, all of which have voting rights.














<PAGE>



                                     PART I

Item 1.            Financial Statements


Condensed Consolidated Balance Sheet                                 F-1

Condensed Consolidated Statements of Operations                      F-2

Condensed Consolidated Statements of Cash Flows                      F-3

Notes to the Financial Statements                                    F-4















<PAGE>


<TABLE>
<CAPTION>
                         Surgical Safety Products, Inc.
                      Condensed Consolidated Balance Sheet
                               September 30, 2001
                                   (Unaudited)


                                        ASSETS
<S>                                                                             <C>
Current assets:
  Property held for sale                                                        $             27,600
                                                                                --------------------

Intangible assets                                                                             74,381
                                                                                --------------------

                                                                                $            101,981
                                                                                ====================

                       LIABILITIES AND STOCKHOLDERS' (DEFICIT)

Current liabilities:
  Accounts payable and accrued expenses                                         $            459,591
  Bank overdraft                                                                                 512
  Deferred revenue                                                                            30,602
  Notes payable - shareholders                                                                41,563
  Notes payable                                                                              478,026
                                                                                --------------------
      Total current liabilities                                                            1,010,294
                                                                                --------------------

Stockholders' (Deficit):
  Common stock, $.001 par value, 100,000,000
   shares authorized, 20,022,889 shares
   issued and outstanding                                                                      20,022
  Additional paid-in capital                                                                4,449,862
  Accumulated deficit                                                                      (5,378,197)
                                                                                ---------------------
                                                                                             (908,313)
                                                                                ---------------------
                                                                                $            101,981
                                                                                ====================
</TABLE>







      See the accompanying notes to the consolidated financial statements.

                                      F-1


<PAGE>




<TABLE>
<CAPTION>
                         Surgical Safety Products, Inc.
                 Condensed Consolidated Statements of Operations
         Three Months and Nine Months Ended September 30, 2001 and 2000
                                   (Unaudited)

                                                                        Three Months                      Nine Months
                                                                    2001             2000             2001            2000
                                                                -------------   -------------    -------------    -------------
<S>                                                              <C>            <C>              <C>              <C>
Revenue                                                          $      3,156   $      58,556    $     188,995    $     518,041
                                                                -------------   -------------    -------------    -------------
Costs and expenses:
 Cost of sales                                                              -               -           18,093                -
 Research and development                                                   -          11,250                -           44,431
 Loss on impairment of assets                                               -               -           71,973                -
 Interest Expense                                                       3,164          25,385           23,461          237,082
 Operating expenses                                                    12,697         442,571          314,350        1,217,009
                                                                -------------   -------------    -------------    -------------
                                                                       15,861         479,206          427,877        1,498,522
                                                                -------------   -------------    -------------    -------------

(Loss) from operations                                                (12,705)       (420,650)        (238,882)        (980,481)
                                                                -------------   -------------    -------------    -------------

Other income and (expense):
 Loss on the disposition of property and equipment                       (174)        (59,196)            (174)         (59,196)
                                                                -------------   -------------    -------------    -------------
                                                                         (174)        (59,196)            (174)         (59,196)
                                                                -------------   -------------    -------------    -------------

Net (loss)                                                       $    (12,879)  $    (479,846)   $    (239,056)   $  (1,039,677)
                                                                -------------   -------------    -------------    -------------

Per share information - basic and fully diluted

Net (loss) per share                                             $      (0.00)  $       (0.04)   $       (0.01)   $       (0.09)
                                                                =============   =============    =============    =============

Weighted average shares outstanding                                20,022,889      12,627,526       18,956,190       12,231,494
                                                                =============   =============    =============    =============
</TABLE>


      See the accompanying notes to the consolidated financial statements.

                                      F-2




<PAGE>



<TABLE>
<CAPTION>
                 Condensed Consolidated Statements of Cash Flows
                    Nine Months Ended July 31, 2001 and 2000
                                   (Unaudited)

                                                                          2001                  2000
                                                                  -------------------     -----------------
<S>                                                               <C>                     <C>
Cash flows from operating activities:
  Net cash (used in) operating activities                          $         (139,130)    $        (547,889)
                                                                  -------------------     -----------------

Cash flows from investing activities:
  Net cash provided by (used in) investing activities                               -              (157,145)
                                                                  -------------------     -----------------

Cash flows from financing activities:
   Increase in (repayment of) shareholder loans                                 5,371               (15,000)
   Bank overdraft                                                                 512                     -
   Proceeds from note payable                                                  81,000               650,000
   Deferred financing costs                                                         -               (70,000)
                                                                  -------------------     -----------------

  Net cash provided by financing activities                                    86,883               565,000
                                                                  -------------------     -----------------

Increase (decrease) in cash and cash equivalents                              (52,247)             (140,034)

Cash and cash equivalents, beginning of period                                 52,247               516,799
                                                                  -------------------     -----------------

Cash and cash equivalents, end of period                           $               -      $         376,765
                                                                  ===================     =================
</TABLE>















      See the accompanying notes to the consolidated financial statements.


                                      F-3


<PAGE>


                         SURGICAL SAFETY PRODUCTS, INC.

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                               SEPTEMBER 30, 2001
                                   (UNAUDITED)

(1)  Basis Of Presentation

The accompanying unaudited financial statements have been prepared in accordance
with generally  accepted  accounting  principles  ("GAAP") for interim financial
information  and Item 310(b) of  Regulation  S-B. They do not include all of the
information and footnotes required by GAAP for complete financial statements. In
the opinion of management,  all adjustments (consisting only of normal recurring
adjustments) considered necessary for a fair presentation have been included.

The  results  of  operations  for the  periods  presented  are  not  necessarily
indicative  of the  results  to be  expected  for the  full  year.  For  further
information, refer to the financial statements of the Company as of December 31,
2000 and for the two years then ended,  including notes thereto  included in the
Company's Form 10-KSB.

The accompanying  consolidated  financial statements include the accounts of the
Company and its subsidiaries.  Intercompany  transactions and balances have been
eliminated in consolidation.

(2)  Earnings Per Share

The Company  calculates net income (loss) per share as required by SFAS No. 128,
"Earnings per Share." Basic earnings  (loss) per share is calculated by dividing
net income (loss) by the weighted  average  number of common shares  outstanding
for the period.  Diluted earnings (loss) per share is calculated by dividing net
income  (loss) by the  weighted  average  number of common  shares and  dilutive
common stock equivalents outstanding.

(3)  Impairment of Long Lived Assets

Long lived  assets and  certain  identifiable  intangibles  held and used by the
Company are reviewed for possible  impairment  whenever events or  circumstances
indicate the carrying  amount of an asset may not be recoverable or is impaired.
Management had determined  that in June 2001 that all property and equipment not
held for sale should be written off. Accordingly,  an impairment loss of $71,973
was recorded in June 2001.

(4)  Income Taxes

The Company  accounts for income taxes under  Statement of Financial  Accounting
Standards No. 109 (FAS 109),  "Accounting for Income Taxes",  which requires use
of the  liability  method.  FAS  109  provides  that  deferred  tax  assets  and
liabilities  are  recorded  based on the  differences  between  the tax bases of
assets and  liabilities  and their  carrying  amounts  for  financial  reporting
purposes,  referred  to  as  temporary  differences.  Deferred  tax  assets  and
liabilities at the end of each period are determined using the currently enacted
tax rates  applied to taxable  income in the periods in which the  deferred  tax
assets and liabilities are expected to be settled, or realized.

The Company's deferred tax asset resulting from net operating loss carryforwards
is fully offset by a valuation  allowance.  The Company has recorded a valuation
allowance to state its deferred tax assets at estimated net realizable value due
to the uncertainty related to realization of these assets through future taxable
income.

                                       F-4

<PAGE>





The provision for income taxes differs from the amount  computed by applying the
statutory rate of 34% to income before income taxes due to the effect of the net
operating loss.

(5)  Long Term Debt

On February 7, 2001,  the  investment  banking  firm which held the  outstanding
notes payable at December 31, 2000,  converted $230,000 of principal and $18,570
of  accrued  interest  to  662,854  shares of the  Company's  common  stock.  In
addition,  on  February  7, 2001 the Company  executed a loan  cancellation  and
settlement  agreement  effectively  ending the line of credit agreement with the
investment banking firm. Pursuant to the agreement,  on April 3, 2001 the lender
converted an additional $243,665 of principal and $19,601 of accrued interest to
702,043 shares of the Company's  common stock.  At September 30, 2001 the amount
owed to the lender was $351,081,  including accrued interest. In accordance with
the agreement the lender has committed to convert the remaining balance into the
Company's common stock as soon as possible.

(6)  Subsequent Event

On September 15, 2001, the wholly owned  subsidiary of Surgical Safety Products,
Inc. (the  "Company"),  OIX, Inc.  ("OIX") and the Company executed an Agreement
and Plan of Merger and  Reorganization  (the "Agreement")  with C5 Health,  Inc.
("C5") to complete a reverse  triangular  merger  effective on the filing of the
Articles of Merger with the States of Delaware and Florida.  Such  articles were
filed on October  26,  2001.  Under the  Agreement,  OIX merged  into C5 and the
Company  acquired  100% of the  outstanding  common  stock of C5 in exchange for
20,022,889  shares of common stock of the  Company.  Immediately  following  the
effective date of the merger on October 26, 2001,  there were 40,045,778  shares
of the Company's common stock issued and outstanding.  C5 is a transaction-based
healthcare e- business and  information  services  company  located in Sarasota,
Florida.    C5   operates   several    products,    including    Meditrader.com,
Health24News.com, and Salud.com.

The Company  will  account for this  transaction  using the  purchase  method of
accounting.  The Company began consolidating the operations of C5 on October 26,
2001.

Summarized financial  information  (unaudited and subject to purchase allocation
adjustments)  for C5 as of September 30, 2001 and for the nine months then ended
follows (in thousands):

<TABLE>
<S>        <C>                                      <C>
           Total Assets                             $   993
           Total Liabilities                        $ 1,122
           Revenues                                 $     -
</TABLE>



                                       F-5

<PAGE>



Item 2. Management's Discussion and Analysis of Results of Operations.

General

     The Company's (OTC BB: SSPD) overall mission is the research,  development,
production and distribution of innovative  products and services for healthcare.
Consisting  of both  traditional  products and  innovative  business-to-business
e-solutions,  the  common  goal is a safer and more  efficient  environment  for
healthcare workers,  manufacturers and patients.  Originally formed as a medical
device company,  Surgical shifted focus to being an e-company when the Company's
management recognized an untapped market niche:  responding to the critical need
for immediate communication and access to information in healthcare.

     During the last quarter, the Company was relatively inactive as it prepared
for the  acquisition of all of the shares of C5 Health Inc. ("C5") by its wholly
owned subsidiary,  OIX, Inc. Agreements were executed September 15, 2001 to take
effect upon the filing of the Articles of Merger with the States of Delaware and
Florida.  Such filings were made on October 26, 2001. Pursuant to the merger, C5
was the  surviving  corporation.  In  exchange  for all of the shares in C5, the
Company issued 20,022,889 shares of stock to C5's eleven (11) shareholders. Post
merger the Company has 40,045,778 shares outstanding .

     Since the completion of the C5  transaction,  the Company  reactivated  its
operations  and  currently is providing  its existing  products and services and
those  of C5 to the  medical  industry.  C5  operated  two  divisions;  C5 Media
Enterprises  and C5 Health  commerce.  As  reorganized,  Surgical's  Information
Systems Division will oversee C5's activities and its existing Oasis Information
Exchange  that provides  business-to-business  on-demand  safety and  efficiency
driven e-business and information for healthcare workers.  The Company's Medical
Products  and  Services  Division  will  continue  to develop,  manufacture  and
distribute medical devices.

Information Systems Division

           Oasis Information Exchange

     The Oasis  Information  Exchange ("OIX") strategy is healthcare  e-business
content  aggregation  and  applications  integration  through a virtual  private
network.  It links the entire healthcare  continuum,  which includes  healthcare
workers,   administration,   patients,   and   healthcare   and   pharmaceutical
manufacturers.  Oasis Information Exchange is a true healthcare data center with
multiple  access  points.  It  is  an  Internet-based  virtual  private  network
consisting of points-of-access via Intranet, the Internet,  Internet appliances,
and through  TouchPorts  located  throughout  healthcare  facilities  across the
country.  Although the Company is now focusing on providing its services through
the  Internet,   TouchPorts   remain   available  as  an  alternative   and  are
user-friendly   touch-access   Internet   appliances   which  allow   healthcare
professionals  access to high quality  clinical  reference  and agency  mandated
information services.

     OIX consists of three lines of e-business.  The primary product produced by
OIX is a service that creates customized training applications for virtually any
topic. These web browser- based educational  modules are designed to provide the
end-user with succinct,  current information on any topic within practically any
industry.  As a second  line of  business,  OIX builds  on-line  communities  in
specific target markets positioned as information exchanges. The third line of

                                        1

<PAGE>



business,  a  natural  by-product  of the first  two,  is  Internet  application
development and support services.

     During the third quarter of 2000, the Company realized that it was focusing
too much  attention on the  installation  of hardware  rather than  focusing its
attention  on  its  real  product  -  information.   Due  to  the  increase  and
availability of PC's and Internet  accessibility in the healthcare  environment,
the Company  realized that, while in some cases its OASiS network is needed in a
particular  environment,  by and large,  its larger  market is for its  content.
Essentially  the  Company  changed  from  a  hardware  network  supplier  to  an
information  broker  which will  create an  information  exchange  network for a
defined  healthcare  community  that links the  end-users to the industry  while
adding value to both parties. This is essentially what the Company was doing all
along;  however,  it had focused on the delivery  system for its product  rather
than the product itself.

     The  Company  expects to  generate  revenue  from the OIX  activities  from
sponsorships  of CDs and from  user fees and  advertising  on its  website.  The
Company plans to scale the concept for other niche markets by creating  websites
that cater to a  particular  speciality.  The  Company  will focus on  providing
website and Intranet development.

           C5's Activities

     C5's  principal  business is  transaction-based  healthcare  e-business and
information  services.  C5 operates  Health24News.com  and  Salud.com,  Internet
websites  that  provide  healthcare  information,  the first in English  and the
second in Spanish, and MediTrader.com,  a web-based real- time medical equipment
auction site.

     Health24News.com provides healthcare information and articles on a range of
subjects and current news events on health and healthcare issues; course studies
for healthcare  professionals  ranging from patient care and risk  management to
human  resources  solutions;  and a Health Mall for the purchase of a variety of
medical products ranging from diabetic supplies to alternative medicines.

     Salud.com,   the  Company's  Spanish  language  website,  is  a  healthcare
information  site provides  descriptions  of causes and  preventive and wellness
measures for diseases  ranging from acne to maternity  matters.  Litigation  has
been brought regarding the use of the Salud.com domain name.

     MediTrader.com  is an online  marketplace  for buyers  and  sellers of new,
pre-owned  and  refurbished  medical  equipment,  as well as  various  types  of
medical/surgical supplies. It is intended to replace paper-based, cost intensive
procurement processes with web-based, interactive, time saving solutions. C5 has
an affiliate agreement with MD Depot that links its comprehensive medical supply
catalogue on line into the site.

     On May 22, 2001, C5 acquired assets from Millennium  Health  Communications
Inc.  ("MHC")  including  furniture  and  fixtures,   computer  equipment,   and
approximately  315  domain  names  under an asset  purchase  agreement  that was
amended on  September 1, 2001.  Under the  agreement  with MHC,  payment for the
acquired  assets was made by the  issuance of two (2) secured  promissory  notes
under which title to the acquired assets is subject to a security  interest held
by MHC. Each of the secured  promissory  notes is in the face amount of $500,000
and such notes are due on December 31, 2001 and August 1, 2002.  All of the C5's
domain names are registered with Network Solutions.

                                        2

<PAGE>



Medical Products and Services Division

           SutureMate(R)

     SutureMate(R),  a  patented,   disposable,   surgical  assist  device,  was
initially   introduced  in  1993.  Its  unique  design  facilitates  the  highly
recommended  one-handed  suturing  technique  which is advocated by occupational
safety experts.  When one-handed  suturing is not used, extra steps are required
by the surgeon or the  assistant in cutting the needle free of the suture thread
and extra time and hand  movements  are  required  of the  surgeon  in  manually
adjusting  needles  while  using a needle  holder  in most  suturing  processes.
SutureMate(R)  allows  the  surgeon  to use a safer,  more  efficient  method of
surgical   stitching.   The  product   has   features   which   include  a  foam
needle-cushion, and a suture cutting slot.

     SutureMate(R)  was re-designed in late 1998 and has been re-released  since
demand has increased due to statutory changes relating to needlestick  injuries.
Legislation has been adopted at both the federal and state level. An overview of
state needle safety legislation can be viewed at www.cdc.gov/niosh/ndl-law.html.
This legislation  essentially  requires state agencies with employees at risk to
implement needleless systems and sharps with engineered sharps injury protection
in order to prevent the spread of bloodborne pathogens in the workplace.

     The product was  re-engineered  and updated after  feedback from over 4,000
surgeons and surgical  technologists  who used or reviewed the product since its
inception.  As a result of the re- design,  the Company  believes that there are
new clinical  advantages and that the product can be produced at a significantly
lower manufacturing cost. These beliefs are based on the fact that the re-design
includes  a  tent-like  configuration  with a hidden  cutting  device  contained
between the  adhesive  base and the holding  device.  This allows the surgeon to
separate  the needle from the suture  without a scrub nurse  intervening  with a
scissor.  The cost reduction will result from the fact that the original version
cost  approximately  $6.00 per unit while the new  version  costs  approximately
$1.10 per unit including packaging and sterilization, allowing it to be marketed
in the $5 to $6 range which is more in keeping  with  pricing  for a  disposable
product. Due to its acceptance by user and quality standards, SutureMate(R) is a
"proven" product that complies with current legislation.

     On  Feb  13,  2001,  the  Company   announced  an  agreement  with  DeRoyal
Industries,  Inc. ("DeRoyal")to distribute  SutureMate(R) worldwide.  DeRoyal is
the largest  privately held healthcare  supplier of safety devices with over 250
sales  representatives  worldwide.  Formed in 1973,  DeRoyal is a international,
vertically-integrated supplier of institutional and consumer healthcare products
and services,  with 27 subsidiaries and affiliates in seven states  (California,
Florida,  Georgia,  Oklahoma,  South Carolina,  Tennessee, and Virginia) and ten
countries (Canada, Costa Rica, England,  Estonia,  Germany,  Ireland, Italy, the
Netherlands, Sweden and the United States). DeRoyal's four business units, Acute
Care, Patient Care, Wound Care and OEM (original equipment manufacturer) produce
more than 25,000  products,  including:  rehabilitation  and  therapy  products,
sports  medicine  supports,  orthopedic  bracing and  supports,  fiberglass  and
plaster  casting;  wound care dressings;  unitized  surgical  delivery  systems,
including TracePak and custom procedural trays; surgical accessories;  neonatal,
labor  and  delivery   products;   angiographic,   endoscopic,   anesthesia  and
temperature  monitoring products; as well as manufacturing services in plastics,
textiles,  electrical  manufacturing,   converting  and  sterilization.  DeRoyal
introduced the re-designated SutureMate(R) at AORN in March, placed an order for
8,000 units for which the  Company  was paid when it made  delivery in May 2001.
DeRoyal carries  SutureMate(R)  in its surgical safety  assessory line, which is
being highly promoted in the current environment of blood

                                        3

<PAGE>



borne pathogen concern and increased safety  legislation.  Since the merger, the
Company is rekindling this relationship.

     The Company  continues to ship this  product.  Currently,  the  re-designed
SutureMate(R)  is  manufactured  by  the  Hansen  Plastic  Division  of  Tuthill
Corporation  at their plant  located in  Clearwater,  Florida  ("Tuthill").  The
Company is  continuing  the  process  of  negotiating  additional  manufacturing
sources and original equipment manufacturer sales.

Corporate Developments

     Effective June 7, 2000, the Company's line of credit with SouthTrust in the
amount of $100,000 was renewed through August 12, 2000, with an option to extend
the maturity  until  October 15, 2000 if the Company  pledged a  certificate  of
deposit in the amount of $25,000.  The interest  rate is prime plus 1.5% and the
line is secured by the Company's equipment,  receivables and inventory. The line
is guaranteed  personally by Dr. Swor. The line of credit was renewed on October
15, 2000 and the maturity date is December 31, 2000. The outstanding  balance at
such time was $100,000. The Company pledged an additional $25,000 certificate of
deposit to secure the line. As of December 31, 2000, the outstanding balance was
$100,000.  In the first half of 2001,  the Company  paid down the line of credit
with the two (2)  pledged  certificates  of  deposit  and  $5,000  in cash.  The
Company,  through a loan from Dr. Swor,  paid off the  outstanding  balance plus
accrued  interest on July 27, 2001.  There  currently is $41,563 due to Dr. Swor
for this payment.

     As of the date  hereof,  the  remainder of the  convertible  debt to Thomas
Kernaghan ("TK") under the Loan Agreement made in December 1999 is in the amount
of $316,335 plus accrued and unpaid interest from March 31, 2000.

     The Company  continues to seek  additional  debt or equity  funding.  Until
fully  converted,  interest as it accrues on the TK debt will  increase the long
term debt of the  Company.  The Company is  currently  seeking  other  potential
funding.  In the event additional debt is raised,  the Company will incur future
interest  expense.  The TK  debt,  if  fully  converted  and  all  warrants  are
exercised,  will dilute the interest of existing  shareholders  and in the event
additional  equity is raised,  management may be required to dilute the interest
of existing  shareholders  further or forego a substantial interest in revenues,
if any. In the event that the Company is successful in securing  additional debt
financing,  the  amount  of such  financing,  depending  upon its  terms,  would
increase either the short or long term debt of the Company or both.

     Surgical  executed a Term Sheet with C5 Health Inc. ("C5") on July 10, 2001
whereby C5 agreed to merge into OIX, Inc., the Company's wholly owned subsidiary
The reverse  triangular merger was executed on September 15, 2001 to take effect
upon  completion  of the  filings of the  Articles  of Merger with the States of
Florida and Delaware. Such filings were effective date on October 26, 2001.

     Under the  merger,  the Company  acquired  all of the shares of C5 from the
eleven (11) C5 shareholders in exchange for 20,022,889 shares in the Company and
merged OIX into C5. This issuance  effectively  changed  control in the Company.
The  Company's  shares were issued in  accordance  with Rule 506 of Regulation D
promulgated under the Securities Act of 1933, as amended,  and the Blue Sky laws
of Virginia and Florida.


                                        4

<PAGE>



     In  addition,  the  Company  elected  three (3) new members to its Board of
Directors  to fill  three (3)  vacancies  on the  Board to serve  until the next
shareholder  meeting,  each of whom  had  served  on the  Board  of C5.  William
Danielczyk was elected  Chairman of the Board, and R. Paul Gray and Robert Lyles
were named as Directors to serve along with the existing  Directors,  G. Michael
Swor,  David Swor and James  Stuart.  G. Michael  Swor will  continue as interim
Chief Executive Officer.  Mr. Gray was elected as Secretary and Treasurer and is
the acting Chief Financial Officer until another  qualified  professional can be
hired.  Timothy  Novak was elected as  President  and Chief  Operating  Officer.
Benjamin  Rosenbaum  III, an attorney  licensed  in the State of  Virginia,  was
elected as Vice President and General Counsel.

     As part of the  merger,  Dr.  Swor  executed an  agreement  that  contained
certain lock-up  provisions  regarding his shares and options.  The agreement is
dated October 5, 2001.  Under the agreement,  Dr. Swor is required to consummate
any  sales  of his  shares  in  compliance  with  relevant  securities  laws and
regulations  and he is  prohibited  for a period of 365 days from the closing of
the merger from  selling any of his shares if it will create a daily low trading
price in SSP shares.

     Surgical has been seeking a merger  partner  since the last quarter of 2000
and  particularly  was seeking  qualified  management  to oversee the day to day
operations of the Company as well as synergistic  lines of healthcare  products.
The Company believes that the C5 transaction provides such management.

Discussion and Analysis

     The  Company  was  founded  in 1992  to  combat  the  potential  spread  of
bloodborne pathogenic infections such as HIV and hepatitis. It has broadened its
mission to  research,  develop,  manufacturing,  marketing  and selling  medical
products and services to the healthcare community.

     The  Company  was in  the  development  stage  until  1993  when  it  began
commercial  shipments of  SutureMate(R),  its first  product.  From inception in
June,  1992  through  December  31,  2000,  the  Company  generated  revenues of
approximately  $1,876,000  from a limited number of customers.  Since  inception
through  December  31,  2000,  the Company has  generated  cumulative  losses of
approximately  $5,140,000.   Although  the  Company  experienced  a  significant
percentage  growth in revenues from fiscal 1992 to fiscal 2000, the Company does
not believe  prior  growth rates are  indicative  of future  operating  results.
During the last quarter,  the Company was  relatively  inactive while the merger
with C5 was being  completed.  There can be no assurance that  profitability  or
significant  revenues on a quarterly  or annual  basis will occur in the future.
Moreover,  the Company expects to continue to incur operating  losses through at
least through  fiscal 2001,  and there can be no assurance  that losses will not
continue after such date.

     As discussed in the independent  auditors' report for the fiscal year ended
December 31, 2000,  the  operating  losses  incurred by the Company  raise doubt
about its ability to continue  as a going  concern.  Now that the merger with C5
has been completed,  the Company expects to experience  growth.  During the last
quarter,  the  Company's  reduced  operations  were  funded by bridge  loans and
residual  sales and the  Company's  net loss  continued,  although  at a reduced
level.  The  inactive  period  caused  a  significant  strain  on the  Company's
management,  financial and other resources.  The Company's ability to manage any
possible future growth,  should it occur,  will depend on a large part, upon the
success of the now completed merger with C5. There can

                                        5

<PAGE>



be no  assurance  that  significant  problems  will not occur as a result of the
merged  operations  of the  Company  and C5 and any such  problems  could have a
material  adverse  effect on the  Company's  business,  financial  condition and
results of  operations.  As a result of the  difficulty in  forecasting  revenue
levels, the Company expects to continue to experience  significant  fluctuations
in its  revenues,  costs  and  gross  margins,  and  therefore  its  results  of
operations.

     The Company's  plan of operations for the next twelve months is to focus on
building  revenue from production of its web-enabled  training  applications and
the other products and services offered by the Company and C5.

     In this  regard,  Surgical  and C5  decided to proceed  with  merger  plans
because there are certain  synergies that are expected to result from the merged
companies.  The merger brings additional  management and operations  support, as
well as access to growth  capital  and  synergistic  product  lines  related  to
transaction-based healthcare e-business, high-traffic healthcare website portals
and proprietary medical websites and physician practice management software.  It
is anticipated that the existing infrastructure and management of C5 can provide
the depth and stability in management  Surgical has been seeking to improve over
the last few years. As a result of these features,  management believes that the
combination  of its  goals and those  previously  formulated  by C5 will be more
attractive to outside  financial  sources.  C5 will need to further  develop its
existing IS/IT human resource and computer  hardware  infrastructure in order to
support the  development  and deployment of all existing and future  web-enabled
product  lines.  This can be  accomplished  through  either  internal  growth of
technical   staff  and  physical   plant,   vendor   relationship  or  strategic
acquisition.

     In the short term, to fund operations through fiscal 2001, the Company will
be relying upon its revenues and will be seeking additional funds from strategic
alliances with potential clients, its shareholders,  from additional third party
financing or seek third party debt or equity  financing other than those planned
by the current  anticipated  agreements.  The Company  maintained  minimal staff
while the merger was awaiting completion. As a result of the merger, the Company
now employees eight (8) people under the  arrangement  with Gevity on a full and
part-time basis.

     As discussed in Note 21 to the  Financial  Statements  for the period ended
December  31,  2000,  if the  financing  referred to above is not  secured,  the
recoverability of the recorded asset amounts may be impaired.

     Earlier in 2001,  the  Company  had  required  between $5 and $8 million in
additional capital in the form of debt or equity to fund the continued expansion
of the  Oasis  system  and its  development  to  meet  increased  demand  and to
implement its plans for increased  marketing of its medical device products.  It
is anticipated  that with the merger of C5, the needs of the Company are reduced
to between $2 and $5 million because the synergistic benefits of both companies'
products and services should enhance revenue production and provide economies of
scale to reduce  expenses and gain new business.  Also, C5 brings an established
physical plant,  which includes a fully  integrated NT Network,  e-mail hosting,
web hosting and internal web development  capability.  There can be no assurance
that any long-term financing will be available to the Company or that it will be
on terms that the Company may seek.

Results of Operations for the Nine Months Ended September 30, 2001 and 2000


                                        6

<PAGE>



Overview

     From its inception, the Company has incurred losses from operations.  As of
September 30, 2001, the Company had cumulative net losses totaling approximately
$5,400,000. During fiscal 2000, management shifted its focus to the marketing of
its proprietary  products,  especially those  associated with Oasis  Information
Exchange.  During the last quarter, the Company was relatively inactive while it
awaited the  completion  of the merger of C5 with its wholly  owned  subsidiary,
OIX, Inc.

Financial Position

     As of  September  30,  2001,  2000,  the  Company  had a deficit of working
capital of approximately  $908,000,  as compared to a working capital deficit of
approximately  $11,000  at  September  30,  2000.  This  increase  in deficit is
primarily due to  operational  focus on  reorganization  activities  and limited
working capital during the period.

Revenues

     For the nine months  ended  September  30,  2001 and 2000,  the Company had
total  revenues of $188,995 and  $518,041,  respectively.  Revenues for the nine
months  ended  September  30,  2001  consist  of  sale  of   SutureMate(R)   and
amortization of deferred revenue.  For the nine months ended September 30, 2000,
revenues were derived from primarily from license and production fees.

Selling, General, and Administrative Expenses

     For the nine months ended September 30, 2001,  operating expenses decreased
by  approximately  $903,000 or 74% from  $1,217,000  for the nine  months  ended
September  30, 2000.  This  decrease is primarily  related to relative  inactive
status and reduction of operations while awaiting the C5 merger.

     In  the  past,  the  Company  focused  on the  design  and  development  of
proprietary  products  and  services.  For fiscal 2001,  the Company  planned to
launch an  aggressive  marketing  plan that was  designed to increase  worldwide
sales of its  products;  however,  such plan was  suspended  while  the  Company
engaged in its attempt to merge with C5.

Liquidity and Capital Resources

     The financial  condition,  liquidity  and capital  resources of the Company
should be assessed  in context  with the ability of the Company to continue as a
going concern as discussed in the  independent  auditors'  report for the fiscal
year ended December 31, 2000.

     The  Company's  operations  have been  funded  primarily  from cash flow of
approximately  $87,000  from  bridge  loans and loans from  related  parties.  A
significant  amount of those funds were expended on merger related  ventures and
joint  operations  with C5. This allowed the Company to continue its essentially
inactive operations while now awaiting the C5 merger.

     The company had a line of credit with  SouthTrust in the amount of $100,000
that was renewed  through August 12, 2000, with an option to extend the maturity
until October 15, 2000

                                        7

<PAGE>



if the Company  pledged a certificate  of deposit in the amount of $25,000.  The
interest  rate was prime  plus 1.5% and the line was  secured  by the  Company's
equipment,  receivables and inventory. The line was guaranteed personally by Dr.
Swor.  The line of credit was renewed on October 15, 2000 and the maturity  date
was December 31, 2000. The  outstanding  balance at such time was $100,000.  The
Company pledged an additional $25,000 certificate of deposit to secure the line.
As of December 31, 2000, the outstanding balance was $100,000. In the first half
of 2001,  the  Company  paid  down the line of credit  with the two (2)  pledged
certificates  of deposit  and $5,000 in cash.  As of July,  2001,  the  Company,
through  a loan  from Dr.  Swor,  paid off the line of  credit  and all  accrued
interest through a settlement agreement with SouthTrust Bank. There currently is
$41,563 due to Dr. Swor for this payment.

     There  was no net  cash  used  for  investing  for the  nine  months  ended
September 30, 2001.

     In the short term, to fund  operations  through the balance of fiscal 2001,
the Company will rely on revenues and will seek additional  funds from strategic
alliances with potential clients, its shareholders,  from additional third party
financing or seek third party debt or equity  financing other than those planned
by the current agreements.  Additionally,  the Company anticipates that revenues
will continue to be generated  from the sale of  SutureMate(R)  and now revenues
from the C5 activities.  Provided that revenues are sufficient and/or additional
funding is secured,  the  Company  believes  that it can meet its capital  needs
through year end.  There can be no assurance that the Company will be successful
in these efforts.

Forward-Looking Statements

     This Form 10-QSB includes  "forward-looking  statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities  Exchange  Act of  1934,  as  amended.  All  statements,  other  than
statements of historical  facts,  included or  incorporated by reference in this
Form 10-QSB which address  activities,  events or developments which the Company
expects or anticipates will or may occur in the future, including such things as
future capital  expenditures  (including the amount and nature thereof),  demand
for the Company's  products and services,  expansion and growth of the Company's
business and operations, and other such matters are forward-looking  statements.
These  statements  are based on certain  assumptions  and  analyses  made by the
Company in light of its  experience  and its  perception of  historical  trends,
current conditions and expected future  developments as well as other factors it
believes are appropriate in the circumstances.  However,  whether actual results
or developments will conform with the Company's  expectations and predictions is
subject  to a number of risks and  uncertainties,  general  economic  market and
business  conditions;  the business  opportunities (or lack thereof) that may be
presented  to and pursued by the  Company;  changes in laws or  regulation;  and
other   factors,   most  of  which  are  beyond  the  control  of  the  Company.
Consequently, all of the forward-looking statements made in this Form 10-QSB are
qualified by these cautionary  statements and there can be no assurance that the
actual results or  developments  anticipated by the Company will be realized or,
even if substantially  realized, that they will have the expected consequence to
or effects on the Company or its business or operations.




                                        8

<PAGE>



PART II

Item 1.  Legal Proceedings.

     On March 13, 2001,  the Company was served with a Summons and  Complaint by
IBM in an action  entitled  International  Business  Machines v. Surgical Safety
Products  Inc.  (The  "Action").  The Action was brought in the Circuit Court in
Sarasota  Florida.  In the Action,  IBM has  brought  four (4) causes of action,
namely,  breach  of  contract,  implied  contract,  account  stated  and  unjust
enrichment.  Each cause of action relates to the contract  between  Surgical and
IBM  relative to the delivery of services  and  equipment.  Surgical had entered
into the arrangement  with IBM to meet its  commitments to US Surgical.  When US
Surgical  failed to perform as  expected,  Surgical  sought  termination  of the
arrangement  with IBM.  Effective July 14, 2000,  this contract was  terminated.
Surgical has been working with IBM in an effort to settle this matter.  Surgical
has filed an answer denying the allegations,  interposing  affirmative  defenses
and has filed  counterclaim  against IBM for an accounting of funds paid to IBM.
IBM has answered the  counterclaim  and  interposed  affirmative  defenses.  The
litigation is in the  discovery  stage.  IBM is seeking  payment of in excess of
$600,000 for invoices  principally related to software and labor associated with
implementing the US Surgical  Agreement.  Should IBM prevail in this Action,  it
would have a material adverse effect upon Surgical's  financial  condition.  The
Company  believes  it has an absolute  defense to the breach of  contract  claim
since the agreement  provided that the Company could  terminate and provided the
payments required for such termination.  Further the agreement required that the
Company  approve  all work  prior to  performance  and the work for which it was
invoiced was not approved. The implied contract and unjust enrichment claims can
only go forward  if the there is no valid  contract  since they are  alternative
pleadings.  The Company  believes that it has just and  meritorious  defenses to
this action. The Action is in the discovery stage.

     C5's  right to use the  Salud.com  domain  name is  subject  to  litigation
currently  pending in U.S.  District Court for the Southern District of Florida.
C5 acquired the domain name Salud.com as part of the asset acquisition from MHC.
It also acquired any liabilities  relating to such acquired assets that arise on
or after the closing.  In a case  entitled  Salu,  Inc. v.  Salud.com,  Inc. and
Millennium Health Communications,  Inc., Case No. 00-3877-CIV, the plaintiff has
listed four (4) causes of action alleging Infringement of a Registered Trademark
under  15 USC  ss.1114,  Infringement  of a  Registered  Trademark  under 15 USC
ss.1125(a),  Dilution of a Famous Mark and  Violations  of Common Law  Trademark
Rights. The plaintiff is seeking declaratory and injunctive relief,  transfer or
forfeiture  of the domain  name,  monetary  damages,  an  accounting  and treble
damages  and other  damages  permitted  under 15 USC  ss.1117.  The  plaintiff's
complaint  was never served and the first amended  complaint  that was served in
the spring 2001 did not include MHC. The defendant made a motion to dismiss that
was denied and thereafter  filed an answer with  affirmative  defenses.  It then
brought a motion for summary  judgment on the basis that the word "salud"  means
health in Spanish and therefore there is no basis for an infringement  claim for
the use in the domain name. While the motion was pending,  the plaintiff filed a
second  amended  complaint  in August 2001 adding MHC.  The court ruled that the
summary judgment was moot in light of the second amended complaint. MHC filed an
answer with  affirmative  defenses and the defendants  have renewed their motion
for summary  judgment  to which is attached  affidavit  evidence  from  language
experts  as to the common  usage of the word  "salud" in  Spanish.  This  motion
currently is pending.  In the event the motion is denied, the defendants believe
they will prevail at trial. However, should judgment be found for the plaintiff,
C5 could lose the right to the  domain  name  Salud.com  and could be liable for
profits and treble  damages.  Should this  occur,  this could have a  materially
adverse effect upon the Company.

     The Company knows of no other legal  proceedings  to which it is a party or
to which any of its property is the subject,  which are pending,  threatened  or
contemplated or any unsatisfied judgments against the Company.


                                        9

<PAGE>



Item 2. Changes in Securities and Use of Proceeds

     There were no changes in the  Company's  securities  in the  quarter  ended
September 30, 2001.

Item 3.  Defaults in Senior Securities

           None

Item 4. Submission of Matters to a Vote of Security Holders.

     No matters were  submitted  to the  Security  Holders for a vote during the
quarter ended September 30, 2001.

Item 5. Other Information

     On November  16,  2001,  the  Company  filed on Form 8K notice of change of
accountants. On November 15, 2001, the Board of Directors voted not to reappoint
Kerkering,  Barbario & Co., PA as its independent  accountants.  This action was
taken principally  because the Company has undergone a change of control and the
Board of Directors  became more familiar  with another  auditing firm during the
transition period. The Company has engaged the firm of Kingery Crouse & Hohl, PA
Certified  Public  Accountants,  4350 West  Cypress  Street,  Suite 275,  Tampa,
Florida 33607, Telephone (813) 874-1280, as its independent auditors.

Item 6.  Exhibits and Reports on Form 8-K

(a)  The exhibits  required to be filed herewith by Item 601 of Regulation  S-B,
     as described in the following index of exhibits, are incorporated herein by
     reference, as follows:

<TABLE>
<CAPTION>
Exhibit No.             Description
--------------------------------------------------------------------------
<S>            <C>
2.1             Agreement and Plan of Merger and Reorganization between Surgical Safety
                Products, Inc., OIX, Inc.  and C5 Health Inc dated September 15, 2001 effective
                October 26, 2001 [14]

3.(I).1         Articles of Incorporation of Surgical Safety Products, Inc., a Florida corporation filed
                May 15, 1992 [1]

3.(I).2         Articles of Amendment filed December 9, 1992 [1]

3.(I).3         Articles of Amendment filed July 19, 1994 [1]

3.(I).4         Articles of Amendment filed October 11, 1994 [1]

3.(I).5         Articles of Incorporation of Sheffeld Acres, Inc., a New York Corporation filed May
                7, 1993 [1]

3.(I).6         Articles of Merger filed in the State of Florida October 12, 1994 [1]

3.(I).7         Certificate of Merger filed in the State of New York February 8, 1995 [1]

3.(I).8         Certificate to Do Business in the State of Florida filed April 11, 1995 [1]
</TABLE>

                                  10

<PAGE>



<TABLE>
<S>            <C>
3.(I).9         Certificate of Amendment filed May 1, 1998 [1]

3.(I).10        Certificate of Amendment filed February 28, 2000 [7]

3.(II).1        Bylaws of Sheffeld Acres, Inc., now known as Surgical Safety Products, Inc. [1]

3.(II).2        Amended Bylaws of Surgical Safety Products, Inc. [2]

10.1            Acquisition of Endex Systems, Inc. d/b/a/ InterActive PIE dated December 8, 1997
                [1]

10.2            Prepaid Capital Lease Agreement with Community Health Corporation relative to
                Sarasota Medical Hospital OASiS Installation dated January 30, 1998 [1]

10.3            Letter of Intent with United States Surgical Corporation dated February 12, 1998 [1]

10.4            Form of Rockford Industries, Inc. Rental Agreement and Equipment Schedule to
                Master Lease Agreement [1]

10.5            Ad-Vantagenet Letter of Intent dated June 19, 1998 [1]

10.6            Distribution Agreement with Morrison International Inc. dated September 30, 1996
                [1]

10.7            Distribution Agreement with Hospital News dated August 1, 1997 [1]

10.8            Clinical Products Testing Agreement with Sarasota Memorial Hospital dated January
                30, 1998 [1]

10.9            Real Estate Lease for Executive Offices effective June 1, 1998 [1]

10.10           Employment Agreement with Donald K. Lawrence dated April 1, 1997 [1]

10.11           Employment Agreement with G. Michael Swor dated June 15, 1998 [1]

10.12           Employment Agreement with Frank M. Clark dated June 15, 1998 [1]

10.13           Agreement for Consulting Services with Stockstowatch.com Inc. dated March 30,
                1988 [1]

10.14           Form of Employee Option Agreement dated July 1994 [1]

10.15           Form of Employee Option Agreement dated 1998 [1]

10.16           Form of Consultants Option Agreement dated July 1994 [1]

10.17           Form of Consultants Option Agreement dated 1998 [1]

10.18           Confidential Private Offering Memorandum dated May 30, 1995 [1]
</TABLE>

                                       11

<PAGE>


<TABLE>
<S>            <C>
10.19           Supplement to Private Offering Memorandum dated October 30, 1995 [1]

10.20           Stock Option Agreement with Bay Breeze Enterprises LLC dated April 9, 1998 [1]

10.21           Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
                Bank dated May 2, 1997 [1]

10.22           Agreement between the Company and T. T. Communications, Inc. dated October 15,
                1998 [2]

10.23           Agreement between the Company and U.S. Surgical Corporation dated October 28,
                1998. [2]

10.24           Collaborative Agreement between the Company and Dr. William B. Saye dated
                November 16, 1998. [2]

10.25           Kiosk Information System, Inc. Purchase Order dated November 3, 1998 [2]

10.26           Surgical Safety Products 1999 Stock Option Plan adopted January 1999 [2]

10.27           Form of the Employee Option Agreement under the Surgical Safety Products 1999
                Stock Option Plan dated January 1999 [2]

10.28           Form of the Director, Consultant and Advisor Option Agreement under the Surgical
                Safety Products 1999 Stock Option Plan dated January 1999 [2]

10.29           Verio, Inc. Access Service Agreement dated February 16, 1999. [2]

10.30           Form of Investor Subscription Documents and Agreements relative to the April 1999
                Self Directed Private Placement Offering under Rule 506 of Regulation D. [3]

10.31           Form of the Warrant issued pursuant to the April 1999 Self Directed Private
                Placement Offering under Rule 506 of Regulation D. [3]

10.32           Consulting Agreement dated April 1999 with Koritz Group, LLC. [3]

10.33           Agreement dated April 1999 with KJS Investment Corporation. [4]

10.34           Agreement dated May 1999 with Ten Peaks Capital Corp. [4]

10.35           Private Partner Network Agreement dated July 30, 1999 with US Surgical [5]

10.36           Staff/Client Leasing Agreement dated October 16, 1999, as amended September 15,
                1999 [5]

10.37           Agreement dated July 15, 1999 with Triton Capital Inc.[6]

10.38           Effective December 30, 1999, Loan Agreement, Note, Security Agreement, Lender's
                Warrant, Agent's Warrant, Registration Rights Agreement and Escrow Agreement
                relative to the December 1999 transaction with Thomson Kernaghan & Co., Inc.  and
                Amendment thereto. [7]
</TABLE>

                                       12

<PAGE>


<TABLE>
<S>            <C>
10.39           Effective January 3, 2000 IBM Customer Agreement and Statement of Work. [7]

10.40           Investment Banking Services Agreement dated February 2, 2000 with Dunwoody
                Brokerage Services Inc. [8]

10.41           Consulting Agreement dated February 15, 2000 with Global Development Advisors
                Inc. [8]

10.42           Surgical Safety Products 2000 Stock Option and Award Plan [8]

10.43           Agreement with Steel Beach Productions dated February 29, 2000 [9].

10.44           Agreement with Horizon Marketing Group dated May 16, 2000 [10]

10.45           Agreement with EPIX dated May 25, 2000 [10]

10.46           Amendment to the Company's 2000 Stock Option and Awards Plan dated June 6,
                2000 [10]

10.47           Revolving Loan Agreement, Revolving Note, Security Agreement with SouthTrust
                Bank dated June 7, 2000 [10]

10.48           Agreement with AORN effective July 1, 2000 [10]

10.49           Agreement with Carver Cross dated July 6, 2000 [10]

10.50           Agreement with U.S. Surgical effective June 28, 2000 [11]

10.51           Agreement with Imagyn dated September 18, 2000 [12]

10.52           Agreement with Haemacure dated September 19, 2000 [12]

10.53           Agreement with Storz dated September 29, 2000 [12]

10.54           Agreement with Quantum dated October 6, 2000 [12]

10.55           Agreement with Stryker dated October 9, 2000 [12]

10.56           Property Lease dated October 13, 2000 [12]

10.57           Agreement with GDA dated October 25, 2000 [12]

10.58           Loan Cancellation and Settlement Agreement with Thomson Kernaghan & Co.
                Ltd. effective February 7, 2001 [13]
</TABLE>


                                       13

<PAGE>


<TABLE>
<S>            <C>
10.59           Term Sheet for merger with Emagicsoft Technologies Inc.  dated February, 2001
                [13]

10.60           Selective HR Solutions Agreement dated March 2001. [13]

10.61           DeRoyal Industries, Inc.  Agreement dated 2001 [13]

10.62      *    Lock Out Agreement dated October 5, 2001 between Surgical Safety Products,
                Inc., C5 Health, Inc.  and G.  Michael Swor.

13.1            Definitive Proxy Statement filed February 28, 2000 [8]
--------------------
</TABLE>

[1]  Previously filed with the Company's Form 10SB

[2]  Previously filed with the Company's Amendment No. 1 to the Form 10SB

[3]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     30, 1999

[4]  Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 1999

[5]  Previously filed with the Company's Amendment No. 2 to the Form 10SB

[6]  Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 1999

[7]  Previously filed with the Company's Form S-3 on March 2, 2000.

[8]  Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 1999.

[9]  Previously  filed with the Company's Form 10QSB for the Quarter ended March
     31, 2000.

[10] Previously  filed with the Company's  Form 10QSB for the Quarter ended June
     30, 2000.

[11] Previously  filed with the Company's  Amendment 3 to the Form 10QSB for the
     Quarter ended June 30, 2000.

[12] Previously  filed  with the  Company's  Form  10QSB for the  Quarter  ended
     September 30, 2000.

[13] Previously  filed with the  Company's  Form 10KSB for the fiscal year ended
     December 31, 2000.

[14] Previously filed with the Company's Form 8K filed October 4, 2001.

(b)  Reports on Form 8-K were filed during the quarter ended  September 30, 2001
     as follows:


                                       14

<PAGE>



(1) Form 8K filed October 4, 2001 reporting under Item 5 the execution of the C5
Merger  Agreement  to be  effective  at the time of  filing  with the  States of
Florida and Delaware.

           There were no other Form 8K filings made during this quarter.



                                   SIGNATURES

      In accordance with Section 12 of the Securities Exchange Act of 1934, the
registrant caused this Registration Statement to be signed on its behalf by the
undersigned, thereunto duly authorized.

                   Surgical Safety Products, Inc. (Registrant)


Date: November 19, 2001         By: /s/ R.  Paul Gray
                                ---------------------------------------
                                R.  Paul Gray
                                Secretary, Treasurer
                                and Acting Chief Financial Officer




                                       15